Induced lentiginosis with use of topical calcineurin inhibitors.
نویسندگان
چکیده
tive, technical, and material support: Beach and Wilkinson. Study supervision: Khumalo. Financial Disclosure: None reported. Funding/Support: The original study was supported in part by the North American Hair Research Society (Dr Beach) and the Women’s Dermatologic Society (Dr Beach). Dr Wilkinson is supported by the Medical Research Council (United Kingdom) and performed the laboratory work in facilities partially funded by Wellcome Trust grant 084323 and the Division of Dermatology, University of Cape Town. The cytokines for the current study were funded by a Galderma (South Africa) award for published work 2010 (Dr Khumalo). Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript. Additional Contributions: We are indebted to Gail Todd, FCDerm,PhD,forenablingparticipantrecruitmentandscalp treatments and to Steven Glassman, MD, who supervised the Ottawa Health Research Institute ethics submission.
منابع مشابه
Rosacea-like eruption due to topical pimecrolimus.
Topical calcineurin inhibitors have been used outside their approved indications for a number of conditions, including topical steroid-induced rosacea. However, tacrolimus ointment itself has been reported to trigger rosacea in a small number of cases. We report a case of a rosacea-like eruption in a 39-year-old woman occurring after the use of pimecrolimus cream for 12 months for atopic dermat...
متن کاملTopical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations
Atopic dermatitis (AD) is an inflammatory skin disease commonly affecting children and managed by pediatricians, primary care physicians, allergists, and dermatologists alike. For many years, the only available topical pharmacological treatment was topical corticosteroids. This changed in 2000-2001, when topical formulations of two calcineurin inhibitors (tacrolimus and pimecrolimus) were appro...
متن کامل[Topical pimecrolimus and tacrolimus and the risk of cancer].
In this review the controversy regarding the association between topical pimecrolimus and tacrolimus and the development of tumors is unfolded. After reviewing the literature we conclude that, currently, there is no scientific evidence of an increased incidence of skin cancer, lymphomas or systemic immunosuppression in those patients that use or have used topical calcineurin inhibitors. Publish...
متن کاملTopical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use
Topical calcineurin inhibitors (TCI) are a relatively new class of drugs used in dermatology. There are two drug forms available - tacrolimus 0.03% or 0.1% ointment and 1.0% pimecrolimus cream. The drugs act by inhibiting synthesis of proinflammatory cytokines. The only approved indication for using TCI is treatment of atopic dermatitis. The TCI may be used as an alternative therapy to corticos...
متن کاملTopical Calcineurin Inhibitors in the Treatment of Vitiligo
Vitiligo is the most common depigmenting disorder, with a prevalence of approximately 0.5% in the world population. Almost half of the patients with vitiligo present before 20 years of age. The two sexes are affected equally, and there are no apparent differences according to skin type or race.1,2 On histology, vitiligo is identified by the loss of epidermal melanocytes with absence of inflamma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Archives of dermatology
دوره 148 6 شماره
صفحات -
تاریخ انتشار 2012